Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE

Alternate Symbol(s):  ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


TSX:ATE - Post by User

Comment by MasterAlgaeon Aug 13, 2021 9:24am
132 Views
Post# 33699906

RE:Alternative

RE:Alternative
Avicenna Therapeutics Inc is a private American company that is involved in finding safer NSAID for cancer and anti-inflammatory treatments. They have world-wide patents on a Hydrogen sulfide and Nitric Oxide (NOSH) compound with Aspirin as the backbone which has promising anti-cancer effects.
 
They also have world-wide patents with Naproxen as the backbone AVT-219 which has powerful anti-inflammatory and chemotherapeutic potential.
They appear to not be as advanced with their compounds as Antibe Therapeutics
 
Wild speculation here - but if the private company wanted to go public in the states a reverse takeover could be the way to do it, create a buzz, acquire more patents with whatever Antibe has (?) And become a gaseous mediator company...?

woundedknee wrote:
This company has a huge amount of money now and before it is wasted on chasing rainbows I would suggest partnering with a company or even forming a new company in another sector an dsend Dan out to seed. After all it isn't as though the "poor" guy needs the money. I'm sure he would be given a very generous compensation package. I agree with muto..having Dan stay on sends a bad message to shareholders. The very shareholders that he has seemingly held in disregard for years. jmo


<< Previous
Bullboard Posts
Next >>